Zinzani P.L.; Tani M.; Fanti S.; Stefoni V.; Musuraca G.; Vitolo U.; Perrotti A.; Fina M.; Derenzini E.; Baccarani M., A phase 2 trial of fludarabine and mitoxantrone chemoterapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma, «CANCER», 2008, 112(4), pp. 856 - 862 [articolo]
Zinzani PL; Tani M; Fanti S; Stefoni V; Musuraca G; Castellucci P; Marchi E; Farsad M; Fina M; Pellegrini C; Alinari L; Derenzini E; de Vivo A; Bacci F; Pileri S; Baccarani M., A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients., «ANNALS OF ONCOLOGY», 2008, 19, pp. 769 - 773 [articolo]
Rubello D.; Rampin L.; Banti E.; Grassetto G.; Massaro A.; Cittadin S.; Pavan L.; Cattelan A.M.; Fanti S.; Al-Nahhas A.; Gross M.D.; Alavi A., Antigranulocyte scintigraphy in infected hip prosthesis: the diagnostic importance of delayed 20-24-h imaging and semiquantitative analysis., «NUCLEAR MEDICINE COMMUNICATIONS», 2008, 29(11), pp. 994 - 998 [articolo]
Tsamita C.S.; Golemi A.; Egesta L.; Castellucci P.; Nanni C.; Stefoni V.; Grassetto G.; Rubello D.; Tani M.; Zinzani P.L.; Fanti S., Clinical significance of axillary findings in patients with lymphoma during follow-up with 18F-fluorodeoxyglucose-PET., «NUCLEAR MEDICINE COMMUNICATIONS», 2008, 29(8), pp. 705 - 710 [articolo]
A. Guido; P. Castellucci; F. Bunkheila; C. Fuccio; B. Rombi; C. Nanni; A. Cecconi; S. Fanti; E. Barbieri, Combined 18F-FDG-PET/CT imaging in radiotherapy target delineation for head-and-neck cancer, in: , «NUCLEAR MEDICINE», 2008, 49 suppl 1, pp. 357P - 357P [atti di convegno-abstract]
Ambrosini V.; Tomassetti P.; Castellucci P.; Campana D.; Montini G.; Rubello D.; Nanni C.; Rizzello A.; Franchi R.; Fanti S., Comparison between (68)Ga-DOTA-NOC and (18)F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours., «EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING», 2008, 35, pp. 1431 - 1438 [articolo]
Farace P.; Galiè M.; Nanni C.; Spinelli A.; Fanti S., Contouring carcinomas by FDG-PET: is the role of tumor biology underestimated? In regard to MacManus et al. (Int J Radiat Oncol Biol Phys 2008;71:2-4)., «INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS», 2008, 72, pp. 303 - 304 [replica/breve intervento]
Pantaleo M.A.; Nannini M.; Maleddu A.; Fanti S.; Ambrosini V.; Nanni C.; Boschi S.; Biasco G., Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy.
Review, «CANCER TREATMENT REVIEWS», 2008, 34, pp. 103 - 121 [articolo]
Nanni C; Rubello D; Fanti S., Could choline PET play a role in malignancies other than prostate cancer?, «EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING», 2008, 35, pp. 216 - 218 [replica/breve intervento]
Magini G, Frigerio M, Farsad M, Serra C, Colecchia A, Jovine E, Vivarelli M, Feletti V, Golfieri R, Lodi F, Franchi R, Fanti S, Bernardi M, Trevisani F, Differential diagnosis between focal nodular hyperplasia and hepatocellular adenoma: Potential role of double tracer PET with 11C-Acetate and 18F-FDG, «JOURNAL OF HEPATOLOGY», 2008, 48, pp. 153 - 153 [abstract]
Fanti S.; Castellucci P.; Stefoni V.; Nanni C.; Tani M.; Rubello D.; Ambrosini V.; Zinzani P.L.; Franchi R., Early relapse in a patient with Hodgkin's disease and negative interim FDG-PET., «ANNALS OF NUCLEAR MEDICINE», 2008, 22(5), pp. 429 - 432 [articolo]
Fanti S.; Ambrosini V.; Tomassetti P.; Castellucci P.; Montini G.; Allegri V.; Grassetto G.; Rubello D.; Nanni C.; Franchi R., Evaluation of unusual neuroendocrine tumours by means of (68)Ga-DOTA-NOC PET., «BIOMÉDECINE & PHARMACOTHÉRAPIE», 2008, 62(10), pp. 667 - 671 [articolo]
Zinzani PL; Tani M; Pulsoni A; Gobbi M; Perotti A; De Luca S; Fabbri A;
Zaccaria A; Voso MT; Fattori P; Guardigni L; Ronconi S; Cabras MG; Rigacci L; De Renzo A; Marchi E; Stefoni V; Fina M; Pellegrini C; Musuraca G; Derenzini E; Pileri S; Fanti S; Piccaluga PP; Baccarani M., Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ)., «THE LANCET ONCOLOGY», 2008, 9, pp. 352 - 358 [articolo]
Ambrosini V.; Rubello D.; Nanni C.; Al-Nahhas A.; Fanti S., Ga-68-DOTA-peptides versus F-18-DOPA PET for the assessment of NET patients, «NUCLEAR MEDICINE COMMUNICATIONS», 2008, 29, pp. 415 - 417 [articolo]
Pantaleo MA;Nannini M;Lopci E;Castellucci P;Maleddu A;Lodi F;Nanni C;Allegri V;Astorino M;Brandi G;Di Battista M;Boschi S;Fanti S;Biasco G, Molecular imaging and targeted therapies in oncology: new concepts in treatment response assessment. a collection of cases., «INTERNATIONAL JOURNAL OF ONCOLOGY», 2008, 33, pp. 443 - 452 [articolo]
